BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
Second novel goal for idiopathic pulmonary fibrosis was found utilizing Benevolent AI’s drug discovery platform and chosen for AstraZeneca’s drug …